Simulations Plus (NASDAQ:SLP) Releases FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.07-$1.20 for the period, compared to the consensus earnings per share estimate of $1.01. The company issued revenue guidance of $90-$93 million, compared to the consensus revenue estimate of $90.71 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Performance

NASDAQ:SLP opened at $30.39 on Wednesday. Simulations Plus has a fifty-two week low of $27.07 and a fifty-two week high of $51.22. The company has a market cap of $610.38 million, a price-to-earnings ratio of 62.02 and a beta of 0.80. The stock has a fifty day moving average price of $29.78 and a 200-day moving average price of $34.16.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The firm had revenue of $18.70 million for the quarter, compared to analyst estimates of $19.73 million. During the same period last year, the firm earned $0.18 EPS. The business’s quarterly revenue was up 19.9% compared to the same quarter last year. Research analysts predict that Simulations Plus will post 1.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. BTIG Research lowered their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Stephens initiated coverage on shares of Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target for the company. StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $31.76, for a total value of $635,200.00. Following the completion of the sale, the director now directly owns 3,442,584 shares in the company, valued at $109,336,467.84. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 19.40% of the stock is currently owned by company insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.